GH Guardant Health, Inc. Insider Trading

GH CIO Kumud Kalia sold 1,200 shares for $157,164.00 in two transactions on 2026-06-10 and 2026-06-15, with a single 600-share purchase at $130.76 on 2026-06-15.

Kumud Kalia executed a net sale of 600 shares while holding 40,814 shares post-transaction, representing a -1.4% reduction in his holdings at Guardant Health. The filing comprises 2 separate sales totaling 1,200 shares for $157,164.00 and 1 purchase of 600 shares for $78,456.00, with transactions clustered between 2026-06-10 and 2026-06-15 at prices ranging from $130.76 to $131.08, below the 52-week high of $153.95. His prior sells at GH showed mixed timing: 2 prior sales on 2026-03-04 exhibited 90-day returns of +36.8% and +36.0% respectively, indicating stock appreciation after sale (poorly timed), while timing accuracy across his 3 prior open-market sells stood at 0.00%. The company reported net income of $-112,075,000.00 over its most recent full fiscal year while achieving +32.9% annual revenue growth, underscoring ongoing unprofitability in a high-growth phase.

GH Co-CEO Talasaz sold 260,000 shares for $39.3M via 10b5-1 plan; retains 1.88M shares plus 201,022 in derivative holdings

Amirali Talasaz executed 6 separate sales totaling 260,000 shares for $39,312,654.10 on June 26 and June 29, 2026, at prices ranging from $150.49 to $153.00. This transaction is scheduled under a 10b5-1 trading plan, meaning it was pre-arranged rather than discretionary. Talasaz's non-derivative holdings fell 12.1% to 1,881,336 shares, but he retains 201,022 shares through stock options, so his overall stake remains substantial. The timing occurred as GH's stock appreciated 15.7% over the prior 30 days and 64.6% over 90 days; however, the 10b5-1 flag constrains any inference about forward timing or market judgment. The company reported a net loss of $112,075,000.00 in the latest period despite 32.9% annual revenue growth, reflecting early-stage profitability challenges that warrant investor attention to the company's path to breakeven.

Guardant Health CIO Kumud Kalia sold 5,000 shares at $130.41 on 2026-06-10 for $652,030.00

Kumud Kalia, Chief Information Officer, sold 5,000 shares at $130.41, reducing holdings from 49.5K to 44.5K shares (-10.1%). The stock is currently at $131.62, up +33.7% over 30 days and +54.0% over 90 days. Kalia's prior trades at GH show a mixed timing pattern: two prior sales on 2026-03-04 resulted in 90-day returns of +36.8% and +36.0% respectively, both occurring after the insider sold. His cross-ticker selling history shows an average 90-day return of +36.4% with a 0.00% well-timed rate, indicating prior sales preceded stock appreciation. The company generated $301.7M in quarterly revenue with +32.9% annual growth but remains unprofitable with full-year net income of -$112.1M, presenting a growth story offset by ongoing losses.

Co-CEO Helmy Eltoukhy sells 100,000 shares ($12.6M) across 7 transactions at GH on 2026-06-05

Helmy Eltoukhy, Co-Chief Executive Officer of Guardant Health, executed 7 separate sales totaling 100,000 shares for $12,629,968.55 on a single trading day, reducing his holdings by 100,000 shares from 2,112,919 to 2,012,919 shares. The blended average price of $126.30 across these transactions sits near the current price of $124.89, and notably, the stock is trading at -7.0% from its 52-week high of $134.28, having recently gained +30.5% over the past 30 days and +38.0% over 90 days. At the same ticker, his prior two sales on 2025-12-15 showed mixed timing outcomes (30d +4.6% and +4.4% but 90d -17.6% and -17.8%), while his two sales on 2025-09-09 demonstrated stronger near-term continuation (+30.5% and +38.0% at 30 and 90 days). The company itself remains unprofitable with net income of $-112,075,000.00 on revenue of $301,665,000.00 in the latest quarter, though it is growing revenue at +32.9% annually.

Director Steve E. Krognes sold 9,294 shares of GH at $132.51 on 2026-06-04, reducing holdings by 47.6%.

Steve E. Krognes sold approximately half his stake (9,294 of 19,516 shares) at $132.51, which sits within the 52-week range but near the high end (only -6.5% from the $134.28 peak). The stock has gained 37.7% over the past 90 days and 36.2% over the past 30 days, placing the sale near a recent momentum inflection. Guardant Health remains unprofitable on a full-year basis with net income of $-112.1M, despite robust annual revenue growth of 32.9%, creating tension between growth narrative and near-term profitability. The insider's cross-ticker track record shows 1 prior sell with a 90-day well-timed rate of 0.00%, offering limited predictive signal for this transaction's timing quality.

Director Meghan V. Joyce sold 10,000 shares ($1.3M) on 2026-06-03 via 10b5-1 plan; retains 11.2K shares + 7,908 option shares.

Meghan V. Joyce, a Director at Guardant Health, Inc., executed four separate sales totaling 10,000 shares for $1,269,808.65 at a blended average price of $126.98 on 2026-06-03. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sale was scheduled rather than discretionary. Post-transaction, Joyce retains 11.2K non-derivative shares and 7,908 option shares, preserving a substantial equity stake. The stock currently trades at $133.06, representing a 30-day gain of +48.6% and a 90-day gain of +45.9%, and the company is unprofitable (net income of $-112.1M in its most recent full fiscal year), though it recorded annual revenue growth of +32.9%. The scheduled nature of the sale and the magnitude of the divestiture warrant attention to the underlying fundamentals of a high-growth but currently loss-making biotech firm.

CLO John G. Saia sold 10,000 shares at $125.08 blended average, reducing holdings 21.8% via scheduled 10b5-1 plan.

John G. Saia, Chief Legal Officer at Guardant Health, executed 2 separate sales totaling 10,000 shares for $1,250,835.98 on 2026-05-27 under a pre-arranged 10b5-1 trading plan. The sale reduced his holdings from 45,950 shares to 35,950 shares (a 21.8% reduction). This transaction is scheduled under a 10b5-1 plan, not a discretionary decision, so it reflects plan timing rather than active strategic positioning. Guardant Health trades at $133.22 currently, above the 52-week high of $128.00 and up 60.3% over 30 days and 41.9% over 90 days, while the company posted negative net income of $-112,075,000.00 despite revenue growth of 32.9% annually.

CCO Chris Freeman sells 24.4K GH shares at $118.67; holds 60.0K remaining after -28.9% reduction.

Chris Freeman, Chief Commercial Officer of Guardant Health, sold 24,406 shares for $2.9M on 2026-05-22 at $118.67 per share, reducing his non-derivative holdings by 28.9% to 60,034 shares; he retains 701 shares in option form. The sale occurs at a price 1.0% below the 52-week high of $121.01, with the stock up 34.8% over the prior 30 days and 25.8% over 90 days—a period of substantial appreciation. Notably, across his prior five trades in Guardant Health all executed on 2025-12-05, Freeman achieved a 100% well-timed rate at the 90-day horizon, with all subsequent holdings declining 8.7% to 13.2%, and his cross-ticker track record shows a 100.00% 90-day well-timed rate across 11 prior sells with an average 90-day return of -10.8%. The company remains unprofitable (net income of -$112.1M in the latest quarter) despite solid revenue growth of 32.9% year-over-year and a $15.9B market cap, creating a backdrop where an insider with a demonstrated pattern of selling before subsequent declines is now liquidating a material stake at elevated valuations.

GH CLO John G. Saia sells 20,000 shares for $2.1M via 10b5-1 plan; current price $118.95 vs $106.51 blended sale price

Chief Legal Officer John G. Saia executed 3 separate sales totaling 20,000 shares for $2,130,228.98 on 2026-05-20 at prices ranging from $105.34 to $107.23, under a pre-arranged 10b5-1 trading plan. As scheduled trades, these sales do not reflect discretionary timing decisions by the insider. His post-transaction holdings stand at 45,950 shares, representing a -30.3% reduction versus pre-transaction holdings of 65,950 shares. The company is unprofitable with net income of $-112,075,000.00 over its most recent full fiscal year, though revenue reached $301,665,000.00 and grew +32.9% year-over-year, indicating expansion amid ongoing losses.

Co-CEO Amirali Talasaz sells 210,000 shares (10% of holdings) for $23.1M via 12 scheduled transactions at GH

Amirali Talasaz executed 12 separate sales totaling 210,000 shares for $23,076,690.06 on 2026-05-20 via a pre-arranged 10b5-1 trading plan, reducing his holdings from 2,096,504 to 1,886,504 shares. This scheduled transaction occurred while the stock was up +32.8% over the prior 30 days and +15.4% over 90 days, trading at $118.95 versus the blended sale price of $109.89. The company remains unprofitable on an annual basis (net income $-112,075,000.00 for the most recent full fiscal year) despite strong revenue growth of +32.9% year-over-year and a market cap of $15.8B. Since this sale is part of a pre-arranged plan rather than a discretionary decision, it reflects scheduled portfolio actions rather than reactive decision-making tied to current market conditions.